Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1109 - A Longitudinal Study of a New Point-of-Care Nerve Conduction Device for Quantitative Assessment of Chemotherapy-Induced Peripheral Neurotoxicity

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Ayumu Matsuoka

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

A. Matsuoka1, O. Maeda1, A. Mitsuma1, K. Uehara2, G. Nakayama3, M. Nagino2, Y. Kodera3, Y. Ando4

Author affiliations

  • 1 Clinical Oncology And Chemotherapy, Nagoya University Hospital, 466-8550 - Nagoya/JP
  • 2 Surgical oncology, Nagoya University Hospital, 466-8550 - Nagoya/JP
  • 3 Gastroenterological Surgery (surgery Ii), Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 4 Clinical Oncology And Chemotherapy, Nagoya University Hospital, 466-8560 - Nagoya/JP
More

Resources

Abstract 1109

Background

Chemotherapy-induced peripheral neurotoxicity (CIPN) exacerbates cumulatively and dose-dependently. Assessment of CIPN usually depends on subjective grading scales, such as the Common Terminology Criteria for Adverse Events (CTCAE). We previously validated a newly developed point-of-care nerve conduction device (POCD) for the quantitative assessment of CIPN (Cancer Sci 2016). The aim of the present study was to prospectively assess CIPN using this POCD.

Methods

Patients scheduled to receive 8 cycles of adjuvant CapeOX therapy (capecitabine and oxaliplatin) for colorectal cancer were enrolled. Sural nerve amplitude potentials (SNAP, μV), a quantitative measure of the axonal degeneration, and sural nerve conduction velocity (SNCV, m/s), that of the degree of demyelination, were recorded using a portable and automated POCD (DPN-Check®, Neurometrix Inc., Waltham, MA, USA) at baseline, each cycle of chemotherapy, and within 1 month after the end of chemotherapy. The severity of CIPN was evaluated according to the CTCAE. The total sum of SNAP/SNCV was calculated for each patient, and compared according to each CTCAE grade.Table: 1760P

baseline2nd3rd4th5th6th7th8thafterwards
SNAP (μV)15.2±8.912.7±5.312.8±6.711.9±5.19.8±4.19.2±2.98.4±3.97.7±3.77.4±4.1
SNCV (m/s)52.7±5.652.7±4.453.7±5.152.5±5.950.4±5.248.0±5.847.3±4.146.3±4.446.1±4.7

Results

A total of 39 patients (M/F: 22/17; median age 61 years, range 36-76; worst CTCAE G1/G2/G3: 25/10/4) were enrolled. Mean SNAP/SNCV at baseline, each cycle of chemotherapy, and within 1 month after the end of chemotherapy are shown in the table. SNAP decreased significantly during each cycle of chemotherapy (repeated ANOVA, P < 0.001), whereas SNCV remained relatively unchanged. The mean total sum of SNAP was 112.6±36.8 G1, 69.8±19.2 G2, and 44.8±12.8 G3. The mean total sum of SNCV was 451.1±34.9 G1, 454.2±24.7 G2, and 429.8±30.1 G3. The total SNAP differed significantly among each CTCAE grade (ANOVA, P < 0.001), whereas the total SNCV did not.

Conclusions

This POCD demonstrates SNAP-dominant neuropathy in patients who receive oxaliplatin, indicating axonal degeneration as a mechanism of CIPN.

Clinical trial identification

UMIN000017868.

Legal entity responsible for the study

Nagoya University Hospital.

Funding

Novartis Pharma K.K.

Editorial Acknowledgement

Disclosure

Y. Ando: Honoraria: Yakult Honsha Co., Ltd, Chugai Pharmaceutical Co., Ltd, Mochida Pharmaceutical Co., Ltd.; Research funding: Yakult Honsha Co., Ltd, Chugai Pharmaceutical Co., Ltd, Mochida Pharmaceutical Co., Ltd, Nippon Kayaku Co. Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.